Thursday, February 4, 2016

GSK's first biological Asthma treatment a potential megablockbuster

Nucala was recently approved by the USFDA and EMA for the treatment of patients with severe Asthma of eosinophilic phenotype.
In the base case, Nucala should reach peak sales of $2b.
If Nucala is approved in other indications (COPD, HES) too, it can garner worldwide peak sales of around $3b.
GlaxoSmithKline's (NYSE:GSK) Nucala was recently approved by the USFDA and European Medicine Agency for maintenance treatment of severe asthma patients aged 12 years or older and with an eosinophilic phenotype. Nucala is a biologic and belongs to a new class of drug called IL-5 inhibitors.
A large proportion of severe asthma patients with eosinophilic phenotype remain inadequately controlled by inhaler medication alone. They need additional systemic treatment. Oral corticosteroid is the mainstay treatment for such patients. Such patients are either chronically treated with oral steroid or they are given a short-term oral corticosteroid which is gradually tapered and withdrawn as symptoms subside.
Value Proposition of Nucala  Read More